We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Illumina’s Companion Diagnostic IDs Patients Positive for NTRK Gene Fusions
Illumina’s Companion Diagnostic IDs Patients Positive for NTRK Gene Fusions
San Diego, Calif.-based Illumina has secured a CE mark in Europe for its TruSight Oncology (TSO) comprehensive assay that can now be used as a companion diagnostic to identify cancer patients with a rare gene mutation for treatment with Bayer’s Vitrakvi (larotrectinib).